KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it should be noted that data from only 6 patients with KRAS G12C tumors were available for this analysis.”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [43]
In the citing paper
“Among patients with stage II CRC, a significantly shorter DFS was noted in patients with KRAS G12C than in those with KRASwt (HR 2.03: P = .006).43”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [43]
In the citing paper
“Five studies that reported on tumor sidedness noted that tumors on the right side of the colon were more likely to have KRASm than those that developed on the left side of the colon.43-47”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“With respect to its predictive role, several retrospective analyses of tumour samples in CRC patients receiving anti-EGFR antibody treatment have shown that patients with mutated KRAS did not benefit from anti-EGFR therapy (Lievre et al, 2006; Amado et al, 2008).”
BackgroundSelf-citationKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156 · cited 3×
“In addition, only 13.7% of the study population had distant metastases, the setting for which treatment with anti-EGFR therapy has been approved (Allegra et al, 2009; Heinemann et al, 2009; Jimeno et al, 2009).”
BackgroundInfluentialKirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 2×
“Roth et al (2010) and Ogino et al (2009a) argue that the meta-analyses of Andreyev et al (1998, 2001) substantially suffered from publication bias and possibly resulted in false-positive results because of the number of subset analyses.”
BackgroundResultFrequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Research works printed but not linked: 50
- Adjei AA (2001) Ras signaling pathway proteins as therapeutic targets. Curr Pharm Des 7: 1581–1594 · DOI
- Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O′Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the ′RASCAL II′ study. Br J Cancer 85: 692–696 · DOI · Paper page
- Anwar S, Frayling I, Scott N, Carlson G (2004) Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 91: 1275–1291 · DOI
- Balko JM, Black EP (2009) A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 9: 145 · DOI
- Baynes RD, Gansert J (2009) KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther 16: 554–561 · DOI
- Bazan V, Agnese V, Corsale S, Calo V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A (2005) Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell′Italia Meridionale (GOIM) prospective study. Ann Oncol 16 (Suppl 4): iv50–iv55 · DOI
- Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La FM, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438–1446 · DOI · Paper page
- Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar J (1998) The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 175: 198–202 · DOI
- Conlin A, Smith G, Carey F, Wolf C, Steele R (2005) The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54: 1283–1286 · DOI · Paper page
- Deschoolmeester V, Baay M, Wuyts W, Van ME, Pelckmans P, Lardon F, Vermorken JB (2006) Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. J Clin Lab Anal 20: 52–61 · DOI
- Deschoolmeester V, Van Damme N, Baay M, Claes K, Van ME, Baert FJ, Wuyts W, Cabooter M, Weyler J, Vermeulen P, Lardon F, Vermorken JB, Peeters M (2008) Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. Eur J Cancer 44: 2288–2295 · DOI
- Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A (2008) High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142 · DOI · Paper page
- Elnatan J, Goh HS, Smith DR (1996) C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A: 491–497 · DOI
- Finkelstein SD, Sayegh R, Bakker A, Swalsky P (1993) Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 128: 526–531 · DOI · Paper page
- Giuliani L, Ronci C, Bonifacio D, Di BL, Favalli C, Perno CF, Syrjanen K, Ciotti M (2008) Detection of oncogenic DNA viruses in colorectal cancer. Anticancer Res 28: 1405–1410
- Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes′ B colorectal cancer patients: how much evidence is enough? Ann Oncol 14: 1026–1038 · DOI
- Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. (2009) Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35: 262–271 · DOI · Paper page
- Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558–561 · DOI · Paper page
- Jass JR (2002) Pathogenesis of colorectal cancer. Surg Clin N Am 82: 891–904 · doi:10.1016/s0039-6109(02)00047-6
- Javle M, Hsueh CT (2009) Updates in Gastrointestinal Oncology—insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2: 9 · DOI
- Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27: 1130–1136 · DOI · Paper page
- Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH, Porschen R, Gregor M (2004) Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis 19: 23–42 · DOI
- Kohne CH, Lenz HJ (2009) Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 14: 478–488 · DOI · Paper page
- Kramer D, Thunnissen FB, Gallegos-Ruiz MI, Smit EF, Postmus PE, Meijer CJ, Snijders PJ, Heideman DA (2009) A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell Oncol 31: 161–167
- Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A (2006) High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6: 295 · DOI · Paper page
- Kumar K, Brim H, Giardiello F, Smoot DT, Nouraie M, Lee EL, Ashktorab H (2009) Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res 15: 1155–1161 · DOI
- Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, Validire P, Muleris M, Girodet J, Salmon RJ (1992) Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136–1141 · doi:10.1016/0016-5085(92)90749-o · Paper page
- Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313–5327 · DOI · Paper page
- Losi L, Luppi G, Benhattar J (2004) Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process. Oncol Rep 12: 1221–1225
- Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622–2629 · DOI · Paper page
- Maughan TS, Adams R, Smith CG, Seymour MT, Wilson AM, Meade AM, Fisher D, Madi A, Cheadle J, Kaplan RS (2010) Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J Clin Oncol (Meeting abstract) 28 (Suppl): 3502 · doi:10.1200/jco.2010.28.15_suppl.3502
- Moerkerk P, Arends JW, van DM, de BA, de GA, ten KJ (1994) Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376–3378
- Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413–421 · DOI · Paper page
- Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson III AB, Goldberg RM, Bertagnolli MM, Fuchs CS (2009a) KRAS mutation in III stage colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15: 7322–7329 · DOI · Paper page
- Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS (2009b) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90–96 · DOI · Paper page
- Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha A, Duval A, Hamelin R, Machado J, Schwartz Jr S, Carneiro F, Seruca R (2007) KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26: 158–163 · DOI · Paper page
- Pajkos G, Kiss I, Sandor J, Ember I, Kishazi P (2000) The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 20: 1695–1701
- Peeters M, Price T, Van Laethem JL (2009) Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14: 29–39 · DOI
- Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N (2009) Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 11: 140–147 · DOI
- Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R (2007) K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203: 489–497 · DOI
- Roth A, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2009) Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol (Meeting abstract) 27: 4002 · doi:10.1200/jco.2009.27.15_suppl.4002
- Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van CE, Bosman F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466–474 · DOI · Paper page
- Saif MW, Shah M (2009) K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 7: 45–53, 64
- Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L, Lindblom A (1999) Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81: 190–193 · DOI · Paper page
- Samowitz WS, Curtin K, Coleman LW, Slattery ML (2001) Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10: 917–923
- Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193–1197
- Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247–253 · DOI · Paper page
- Srinivasan M, Sedmak D, Jewell S (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161: 1961–1971 · DOI · Paper page
- Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van CE, Roth A (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15: 390–404 · DOI · Paper page
- Zhao Y, Miyashita K, Ando T, Kakeji Y, Yamanaka T, Taguchi K, Ushijima T, Oda S, Maehara Y (2008) Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1. Gene 423: 188–193 · DOI
Cited by
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Peeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
Self-citationStrickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Deschoolmeester, V, Boeckx, C., Baay, M., Weyler, J., Wuyts, W., Van Marck, E., Peeters, M., Lardon, F., & Vermorken, J. B.
- Venue
- British Journal of Cancer
- Published
- 2010-10-19
- Volume
- 103
- Issue
- 10
- Pages
- 1627-1636
- ISSN
- 0007-0920
- 1532-1827
- Cited by
- 36
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. https://app.cochat.ai/papers/10.1038/sj.bjc.6605959
- The paper
- Deschoolmeester, V, Boeckx, C., Baay, M., Weyler, J., Wuyts, W., Van Marck, E., Peeters, M., Lardon, F., & Vermorken, J. B. (2010). KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605959
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.